A 42% of patients with heart failure have depression symptoms, a common co-morbidity linked to poor quality of life and a bad prognosis. In addition to having an adverse effect on everyday social and domestic activities, 1-3 depressive symptoms significantly…
Enhertu is the first specific treatment for HER2-mutant lung cancer. Enhertu is the chemical name of fam-trastuzumab-deruxtecan-nxki. When referring to the generic medicine name trastuzumab deruxtecan, healthcare practitioners may use the commercial name Enhertu. A drug is chemically joined to…
Venetoclax is a chemotherapy drug that slows the growth of cancer cells in one of three ways. It either kills the cancer cells or stops them from growing or spreading. Giving venetoclax with rituximab may increase the death of cancer…
Cystic fibrosis has inflammation as one of its primary pathological drivers. Current treatments are poor at controlling and halting the progression of inflammatory events, frequently made worse by concurrent infection. Using anakinra, a non-glycosylated recombinant version of IL-1Ra, offers a…